EN
AVM × North China Pharmaceutical (NCPC): Aseptic Transfer Solution Launches at Pharmaceutical Leader, Jointly Setting a New Benchmark for Pharmaceutical Safety
Time : 2025-10-24
Recently, AVM Extraordinary Intelligent Control Equipment Co., Ltd. ("AVM") has reached in-depth cooperation with North China Pharmaceutical Group ("NCPC"), a leading enterprise in China's pharmaceutical industry. Its core product, the Split Butterfly Valve (SBV), has successfully completed on-site installation and verification, building a safe, aseptic, and efficient "lifeline" for powder transfer in NCPC's high-standard pharmaceutical production lines. This cooperation not only represents the synergy of the technical strength and quality pursuit of both parties but also marks the practical application of AVM's aseptic material transfer solutions in top-tier pharmaceutical scenarios, setting a new "compliance + precision + aseptic" cooperation model for the industry.
I. Strong Alliance: Rooted in a Shared Commitment to "Aseptic Excellence"
As a "national team" in China's pharmaceutical industry, NCPC has been deeply engaged in the pharmaceutical field for decades. It has always controlled the entire pharmaceutical production process with strict standards, especially in the aseptic powder transfer link, which has nearly extreme requirements for GMP compliance, material safety, and process stability. It not only needs to eliminate any risk of cross-contamination but also meet the sealing protection requirements for highly active materials (OEB level) while achieving full-batch traceability—posing extremely high challenges to the technical strength and industry experience of partners.
The reason why AVM has become NCPC's preferred partner lies in the shared pursuit of "aseptic excellence" by both parties and the precise alignment of AVM's Split Butterfly Valve (SBV) with the core needs of the pharmaceutical industry:
- Full-dimensional Compliance Certifications: AVM's Split Butterfly Valve strictly adheres to international standards and industry regulations. It not only meets the core requirements of Good Manufacturing Practice (GMP) and Food and Drug Administration (FDA) for pharmaceutical production but also has obtained authoritative certifications such as the European ATEX Directive (for explosive atmospheres) and Pressure Equipment Directive (PED). The entire production process is managed in accordance with the ISO 9001 international quality system (all from core qualification information on the official website), ensuring product compliance from the source.
- Ultimate Aseptic Design: The part of the valve body in contact with the medium is made of 316L stainless steel, with a surface roughness controlled at Ra < 0.4μm, and Ra < 0.8μm for non-contact parts. It is equipped with fluororubber/silicone rubber seals that meet the FDA 21 CFR 177.2660 standard, with a sealing level of OEB4/OEB5 (SBV product parameters on the official website), perfectly adapting to NCPC's transfer needs for highly active and sensitive powders.
- Full Lifecycle Traceability: AVM has established a "from raw material to finished product" comprehensive material certification and batch traceability system . The material source, processing records, and testing data of each SBV can be traced, completely solving the pain point of "difficult material traceability" in the pharmaceutical industry.
- Authoritative Performance Verification: The product has passed independent verification in accordance with the ISPE SMEPAC (International Society for Pharmaceutical Engineering Sealing Performance Measurement Guidelines) , ensuring stable sealing performance and aseptic status during long-term use and providing reliable support for the continuous operation of NCPC's production lines.
II. Precision Implementation: "Zero-error" Control from Engineering Design to On-site Verification
This cooperation with NCPC is not a simple product delivery but a concentrated manifestation of AVM's full-process capabilities in "precision engineering + aseptic services". From early technical communication and solution customization to on-site installation, commissioning, and final verification, the AVM team has always adhered to the "zero-error" standard to ensure that every link meets the strict requirements of the pharmaceutical industry.
During the on-site installation phase, AVM provided solid support for the implementation of the cooperation relying on its internationally advanced manufacturing equipment and processes (core production capabilities on the official website):
- The core components of the valve body are processed by Japan’s Mazak CNC machines and high-precision CNC machining centers from South Korea (production equipment information on the official website), with dimensional accuracy controlled at the micron level. This ensures "seamless connection" with NCPC's existing pipelines during on-site assembly, avoiding contamination risks caused by assembly gaps.
- The installation team strictly followed AVM's aseptic operation specifications. From valve body cleaning and pipeline disinfection to sealing testing, each step was recorded in detail, and the entire process was supervised by NCPC's quality department to ensure compliance with GMP aseptic production requirements.
- During the final verification phase, by simulating actual production conditions, multiple rounds of tests were conducted on the valve's switching performance, sealing integrity, and material residue. All data met or even exceeded the preset standards, successfully passing NCPC's final acceptance.
"The AVM team not only brought products that meet standards but also a deep understanding of pharmaceutical processes," commented the person in charge of the NCPC project. "From solution design to on-site implementation, they have always focused on the core of 'aseptic safety' and considered every detail thoroughly—this is exactly the partner we need."
III. Value Extension: Empowering High-quality Development of the Pharmaceutical Industry with "Systematic Solutions"
For AVM, the cooperation with NCPC is not only a successful project delivery but also a practical verification of the company's concept of "focusing on aseptic, toxic, and hazardous material transfer system solutions". As a modern enterprise integrating design, production, sales, and service, AVM has always been committed to providing integrated "product + service + solution" support for the pharmaceutical, biopharmaceutical, food, chemical, and other industries. This cooperation with NCPC is a typical practice of this concept in the pharmaceutical field.
In today's pharmaceutical industry, where requirements for "asepticity", "safety", and "compliance" are increasingly stringent, AVM is becoming a preferred "aseptic transfer partner" for more pharmaceutical enterprises by virtue of:
- In-depth understanding of international standards such as GMP, FDA, and ATEX;
- Technological iteration of core products such as Split Butterfly Valves, RTP (Restricted Transfer Port) aseptic transfer systems, and diaphragm valves (full-series products on the official website);
- Full-lifecycle service capabilities from early consultation to later operation and maintenance.
This cooperation case with NCPC will also provide valuable experience for AVM to serve more global pharmaceutical customers, helping the industry break through the bottlenecks of aseptic processes and achieve higher-quality development.
Conclusion: Forging Trust with Quality, Creating the Future through Cooperation
"Pursuing development through quality and valuing trust as life" is the core value that AVM has always adhered to (philosophy on the official website). This successful cooperation with North China Pharmaceutical (NCPC) is not only a recognition of AVM's technical strength and service capabilities but also strengthens the company's determination to deepen its presence in the field of aseptic material transfer. In the future, AVM will continue to rely on advanced manufacturing equipment, strict quality control, and a professional technical team to provide higher-quality products and solutions for global customers. It will work hand in hand with more industry-leading enterprises to jointly build a "healthy, safe, and efficient" ecosystem in the pharmaceutical and biotech fields, and fulfill its commitment to "becoming your long-term reliable partner in building a healthier future" (vision on the official website).